IRX Therapeutics

About:

IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases.

Website: https://www.brooklynitx.com

Description:

IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer treatments better. The lead platform technology, IRX-2, is thought to broadly restore the immune system by overcoming cancer-induced immune suppression. The Company believes that its products can play an important role in helping a wide range of cancer treatments improve and extend the lives of patients. It was founded in 1994 and is headquartered in New York.

Total Funding Amount:

$128M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

New York, New York, United States

Founded Date:

1994-01-01

Founders:

John Hadden

Number of Employees:

11-50

Last Funding Date:

2017-08-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai